AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$165.98
1.49 (0.91%)
▲
5d:
+6.09%
30d:
-1.36%
90d:
-12.53%
BUY
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 27, 2026
0d
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AZN shows positive signals but monitor for confirmation. Market pricing in 18.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: AZN shows positive signals but monitor for confirmation. Market pricing in 18.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$426.12
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$264.59
37.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $165.98, which is considered fair relative to its 30-day fair value range of $159.42 to $169.97. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.6) compared to its historical average (26.9). Remarkably, the market is currently pricing in an annual earnings decline of 18.4% over the next few years. This pessimistic expectation contrasts with the company's recent 2.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AZN is in a strong downtrend. The price is approaching resistance at $167.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AZN scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $213.99 (+28.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AZN is in a strong downtrend. The price is approaching resistance at $167.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AZN scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $213.99 (+28.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$159.42 -
$169.97
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.9% below Wall St target ($213.99)
- BULLISH: Bottoming setup score 68/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$159.42 -
$169.97
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$154.53
Resistance Level
$167.25
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.61
Wall Street Target
$213.99
(+28.9%)
Revenue Growth (YoY)
6.4%
Earnings Growth (YoY)
2.5%
Profit Margin
17.0%
Valuation Discount vs History
-18.4% cheaper
PE vs Historical
14.6 vs 26.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-18.4%
(market-implied from PE analysis)
1-Year Target
$149.38
(-10%)
2-Year Target
$134.44
(-19%)
3-Year Target
$121.00
(-27%)
3-Yr Target (if PE normalizes)
(PE: 15→27)
$222.77
(+34%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 13.0%)
$328.95
(+98%)
Base:
(SPY PE: 14.6, Growth: 13.0%)
$239.48
(+44%)
Bear:
(PE: 12.4, Growth: 13.0%)
$203.56
(+23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 24.70 | Current EPS (TTM): $6.66
Bull Case
$308.63
(+86%)
Analyst growth 70.6%, PE expands to 27.2
Base Case
$280.57
(+69%)
Market implied 70.6%, PE stable at 24.7
Bear Case
$111.85
(-33%)
Severe decline -20.0%, PE contracts to 21.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.6 to 26.9
Stabilization Target:
$305.58
(+84.1%)
PE Expansion Potential:
+84.1%
Share & Embed Analysis
Last updated: August 23, 2026 3:44 AM ET
Data refreshes hourly during market hours. Next update: 4:44 AM
Data refreshes hourly during market hours. Next update: 4:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1311 | 37 SELL |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 34 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$276 | 41 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$238 | 42 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$384 | 38 SELL |
